Skip to content

El Agente F\'armaco: A Scalable AI Scientist for Drug Discovery

Nov 2026 · 0 citations
Computer Science Biology

TL;DR

El Agente F\'armaco, an AI scientist that uses modern large language model (LLM) technology to turn discovery goals expressed in everyday language into complex, scalable computational screening workflows, provides a foundation for flexible, scalable drug discovery workflows that connect scientific reasoning with an enduring, traceable record of computational work.

Abstract

Computational drug discovery offers a growing range of tools for proposing and evaluating molecules, but combining them and deciding what to do next still requires substantial expert effort. Here, we introduce El Agente F\'armaco, an AI scientist that uses modern large language model (LLM) technology to turn discovery goals expressed in everyday language into complex, scalable computational screening workflows. The agentic harness selects scientific tools, reviews their results, and adjusts subsequent steps to the target and the user's objectives. Our approach centers on a shared scientific memory: F\'armaco Atlas, which stores molecules, structures, and results together with their provenance -- a record of how they were obtained. The agent uses targeted database queries to retrieve the evidence needed for each decision. A single request can launch calculations for an entire collection of molecules, without requiring a separate LLM decision for every compound. This design limits the information the model must process as screening collections grow, while keeping the underlying results available for inspection and further analysis. The integrated tools support molecule generation, prediction of binding and molecular properties, and searches for compounds available for purchase. In a retrospective comparison with an expert-led campaign, the agent proposed chemically distinct candidates with competitive docking scores and higher calculated drug-likeness under explicitly imposed selection criteria. In a 22-task benchmark against plain tool calls and Codex, the agent achieved the highest observed mean model-judged score, with lower median cumulative token use and peak context. F\'armaco provides a foundation for flexible, scalable drug discovery workflows that connect scientific reasoning with an enduring, traceable record of computational work.

View source

Similar papers

#artificial intelligence Preprint Oct 2026

MADDIE: Multi-Agent Drug Discovery Engine

Drug discovery remains a resource-intensive and time-consuming process, involving billions of dollars and a decade of development to advance a drug to market. While many in silico tools have accelerated this process, operating them still demands substantial time, effort, and expertise from medicinal chemists. Autonomou...

Ye Liu, Reza Averly, Avery Meyer et al. · 0 citations
#artificial intelligence Preprint Oct 2026

MoLRSI: A Recursive Self-Improving AI agent for Molecular Discovery

Molecular discovery requires navigating vast combinatorial search spaces while balancing competing biological objectives. AI agents can automate expert-defined molecular design protocols, but automation alone does not address how to optimize workflows for new tasks or improve their development through experience. Here...

Yi-Kun Zhang, Xi-Wei Cheng, Ming-Ze Yuan et al. · 1 citation
#small language model Open access Sep 2026

MolecureAI: an agentic AI platform for autonomous drug discovery

Accelerating the identification of viable drug candidates across therapeutic areas demands autonomous systems for molecular generation that enforce chemical correctness by structural invariants rather than model capability. We present MolecureAI, an autonomous AI agent architecture for closed-loop drug discovery with c...

M. Chadi, Asmaa Amzil, Hajar Ezzahoud et al. · 0 citations
Open access Oct 2026

Agentic AI-Orchestrated Computational Drug Discovery: A Case-Study-Demonstrated Open-Source Workflow Blueprint

Bringing a new drug to market can exceed $1 billion, and integrated commercial computational-chemistry platforms cost $200,000–$5,000,000 per year, placing them beyond most resource-constrained research groups. We demonstrate that open-source tools with large language model (LLM) orchestration can democratize early-sta...

Budiwan Sumarsono · 0 citations
Open access Nov 2026

Perspectives for building a computational drug discovery program in resource-limited settings

Computational drug discovery is increasingly transforming the way therapeutic candidates are identified, prioritized, and optimized, with advances in artificial intelligence (AI), machine learning, molecular modelling, cheminformatics, and data-driven approaches expanding the possibilities for early-stage drug discover...

Jude Y. Betow, D. N. Nebangwa, Mathieu J. M. Tjegbe et al. · 0 citations
#artificial intelligence Open access Oct 2026

From Benchmark to Bench: Can Agents Survive Real-World Drug Discovery?

Agentic systems increasingly coordinate molecular-design tools, but it is unclear which layer of the stack limits outcomes on real projects. We developed MAGI, an open modular agent that authors objectives, launches and monitors optimization, interprets structure–activity relationships, and revises its strategy accordi...

P. Llompart, Levent Guner, Helen Lai et al. · 0 citations

Related blog posts

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.